Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer

Lung Cancer

Volumn 76, Issue 1, 2012, Pages 26-31

  Ueno, Tsuyoshi ^a   Tsukuda, Kazunori ^a   Toyooka, Shinichi ^a   Ando, Midori ^a   Takaoka, Munenori ^b   Soh, Junichi ^a   Asano, Hiroaki ^a   Maki, Yuho ^a   Muraoka, Takayuki ^a   Tanaka, Norimitsu ^a   Shien, Kazuhiko ^a   Furukawa, Masashi ^a   Yamatsuji, Tomoki ^b   Kiura, Katsuyuki ^a   Naomoto, Yoshio ^b   Miyoshi, Shinichiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

AUY922; EGFR; EGFR TKI; Hsp90; Mesothelioma; NSCLC

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL PROLIFERATION; FLOW CYTOMETRY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPRECIPITATION; ISOXAZOLES; LUNG NEOPLASMS; MICE; RESORCINOLS; TUMOR CELLS, CULTURED;

EID: 84858009160     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.09.011     Document Type: Article

References (30)

1. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
2. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
3. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
4. Toyooka S., Mitsudomi T., Soh J., Aokage K., Yamane M., Oto T., et al. Molecular oncology of lung cancer. Gen Thorac Cardiovasc Surg 2011, 59:527-537.
5. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
6. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
7. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
8. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
9. Solit D.B., Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008, 13:38-43.
10. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007, 32:517-530.
11. Kobayashi N., Toyooka S., Soh J., Yamamoto H., Dote H., Kawasaki K., et al. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer 2011, in press, Epub ahead of print.
12. Shimamura T., Lowell A.M., Engelman J.A., Shapiro G.I. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005, 65:6401-6408.
13. Shimamura T., Li D., Ji H., Haringsma H.J., Liniker E., Borgman C.L., et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008, 68:5827-5838.
14. Sawai A., Chandarlapaty S., Greulich H., Gonen M., Ye Q., Arteaga C.L., et al. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Res 2008, 68:589-596.
15. Nowakowski G.S., McCollum A.K., Ames M.M., Mandrekar S.J., Reid J.M., Adjei A.A., et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006, 12:6087-6093.
16. Sharp S., Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 2006, 95:323-348.
17. Sequist L.V., Gettinger S., Senzer N.N., Martins R.G., Janne P.A., Lilenbaum R., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28:4953-4960.
18. Holzbeierlein J.M., Windsperger A., Vielhauer G. Hsp90: a drug target?. Curr Oncol Rep 2010, 12:95-101.
19. Ramanathan R.K., Egorin M.J., Erlichman C., Remick S.C., Ramalingam S.S., Naret C., et al. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol 2010, 28:1520-1526.
20. Brough P.A., Aherne W., Barril X., Borgognoni J., Boxall K., Cansfield J.E., et al. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008, 51:196-218.
21. Eccles S.A., Massey A., Raynaud F.I., Sharp S.Y., Box G., Valenti M., et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008, 68:2850-2860.
22. Jensen M.R., Schoepfer J., Radimerski T., Massey A., Guy C.T., Brueggen J., et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008, 10:R33.
23. Lee K.H., Lee J.H., Han S.W., Im S.A., Kim T.Y., Oh D.Y., et al. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Sci 2011, 102:1388-1395.
24. Okui T., Shimo T., Hassan N.M., Fukazawa T., Kurio N., Takaoka M., et al. Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma. Anticancer Res 2011, 31:1197-1204.
25. Stingl L., Stuhmer T., Chatterjee M., Jensen M.R., Flentje M., Djuzenova C.S. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. Br J Cancer 2010, 102:1578-1591.
26. Ogino A., Kitao H., Hirano S., Uchida A., Ishiai M., Kozuki T., et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res 2007, 67:7807-7814.
27. Beere H.M. " The stress of dying" : the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004, 117:2641-2651.
28. Gaspar N., Sharp S.Y., Eccles S.A., Gowan S., Popov S., Jones C., et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010, 9:1219-1233.
29. Toyooka S., Pass H.I., Shivapurkar N., Fukuyama Y., Maruyama R., Toyooka K.O., et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001, 61:5727-5730.
30. Toyooka S., Kishimoto T., Date H. Advances in the molecular biology of malignant mesothelioma. Acta Med Okayama 2008, 62:1-7.